
|Articles|December 15, 2005
Glaucoma treatment focus of Novartis deal
Basel, Switzerland—Novartis will work with Senju Pharmaceutical Co. to develop and commercialize a topical treatment for glaucoma.
Advertisement
Basel, Switzerland-Novartis will work with Senju Pharmaceutical Co. to develop and commercialize a topical treatment for glaucoma.
The deal involves Y39983, a rho kinase inhibitor, under sub-license rights granted to Senju by Mitsubishi Pharma Corp.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
PolyActiva and RareSight partner to develop treatments for rare pediatric retinal diseases
2
Kodiak Sciences releases follow-up, 20-week data from APEX study
3
From then to next: Five decades of transformation in ophthalmology
4
4DMT releases positive interim 1.5- to 3.5-year data from phase 1/2 PRISM trial
5


















































.png)


